Open AccessLong-term pegylated interferon-α and its potential in the treatment of melanoma
Author(s) -
Reinhard Dummer,
Joanna Mangana
Publication year - 2009
Publication title -
biologics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 38
eISSN - 1177-5491
pISSN - 1177-5475
DOI - 10.2147/btt.2009.3051
Subject(s) - melanoma , medicine , pegylated interferon , adjuvant , oncology , stage (stratigraphy) , alpha interferon , pharmacokinetics , population , interferon , toxicity , immunotherapy , gastroenterology , immunology , cancer research , cancer , hepatitis c virus , virus , ribavirin , paleontology , environmental health , biology
Conventional interferons including interferon-alpha (IFN-alpha) are cytokines used for years in the treatment of solid tumors and hematological malignancies. Their half-life is short. Pegylated forms of IFN-alpha present an improved pharmacokinetic profile that rendered them the preferred IFNs in hepatitis therapy. In the last decade, pegylated interferons (PegIFNs) have been investigated in melanoma patients. We review the scientific published literature on biology, pharmacokinetics, side effects and clinical applications of PegIFN-alpha in the treatment of stage III and IV melanoma. In the adjuvant setting, PegIFNalpha-2b has significant prolonged distant metastases free survival in patients with microscopic nodal involvement (stage TxN1aM0) and therefore is a promising treatment option in this patient population. In the palliative setting, monotherapy with PegIFNalpha-2alpha can induce complete remissions in a minority of stage IV melanoma patients. The combination of monochemotherapy is feasible and may result in lasting complete remissions. Ongoing research must focus on the identification of patients who mostly benefit, so that unnecessary toxicity would be avoided. Combining PegIFNs and chemotherapy or targeted agents deserves further exploration.